On the other hand, some authors suggested potential benefits from such a therapy, advocating that inhibition of ACE-AT2-AT2R1 downstream pathways could possibly mitigate the thrombo-inflammatory state seen in severe COVID-19 cases. The gene discussed is ACE; the disease is COVID-19.